Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by Crossref.
Powell, M.L.
Town, C.
Henderson, L.
and
Buck, C.
1990.
Determination of marplan in human plasma using high-performance liquid chromatography.
Journal of Chromatography B: Biomedical Sciences and Applications,
Vol. 529,
Issue. ,
p.
237.
Stoudemire, Alan
Moran, Michael G.
and
Fogel, Barry S.
1990.
Psychotropic Drug Use in the Medically Ill.
Psychosomatics,
Vol. 31,
Issue. 4,
p.
377.
Stoudemire, Alan
Moran, Michael G.
and
Fogel, Barry S.
1991.
Psychotropic Drug Use in the Medically Ill.
Psychosomatics,
Vol. 32,
Issue. 1,
p.
34.
1994.
ECT as a treatment for depression in Huntington's disease.
The Journal of Neuropsychiatry and Clinical Neurosciences,
Vol. 6,
Issue. 2,
p.
154.
1994.
The neuropathologic basis of major affective disorders: neuroanatomic insights.
The Journal of Neuropsychiatry and Clinical Neurosciences,
Vol. 6,
Issue. 2,
p.
114.
Feldman, Eleanor
1995.
The new genetics in psychiatry.
Advances in Psychiatric Treatment,
Vol. 1,
Issue. 4,
p.
109.
1996.
ECT in genetically confirmed Huntington's disease.
The Journal of Neuropsychiatry and Clinical Neurosciences,
Vol. 8,
Issue. 2,
p.
209.
Ross, Christopher A.
Margolis, Russell L.
Rosenblatt, Adam
Ranen, Neal G.
Bêcher, Mark W.
and
Aylward, Elizabeth
1997.
Huntington Disease and the Related Disorder, Dentatorubral-Pallidoluysian Atrophy (DRPLA).
Medicine,
Vol. 76,
Issue. 5,
p.
305.
ANPA Committee on Research, A Report of the
Lauterbach, Edward C.
Cummings, Jeffrey L.
Duffy, James
Coffey, C. Edward
Kaufer, Daniel
Lovell, Mark
Malloy, Paul
Reeve, Alison
Royall, Donald R.
Rummans, Teresa A.
and
Salloway, Stephen P.
1998.
Neuropsychiatric Correlates and Treatment of Lenticulostriatal Diseases.
The Journal of Neuropsychiatry and Clinical Neurosciences,
Vol. 10,
Issue. 3,
p.
249.
Leroi, Iracema
and
Michaion, Max
1998.
Treatment of the Psychiatric Manifestations of Huntington's Disease: A Review of the Literature.
The Canadian Journal of Psychiatry,
Vol. 43,
Issue. 9,
p.
933.
Anderson, Karen E.
and
Marder, Karen S.
2001.
An overview of psychiatric symptoms in Huntington’s disease.
Current Psychiatry Reports,
Vol. 3,
Issue. 5,
p.
379.
Slaughter, James R.
Martens, Matthew P.
and
Slaughter, Kathleen A.
2001.
Depression and Huntington's Disease: Prevalence, Clinical Manifestations, Etiology, and Treatment.
CNS Spectrums,
Vol. 6,
Issue. 4,
p.
306-308,325.
Naarding, P.
Kremer, H.P.H.
and
Zitman, F.G.
2001.
Huntington's disease: a review of the literature on prevalence and treatment of neuropsychiatric phenomena.
European Psychiatry,
Vol. 16,
Issue. 8,
p.
439.
Keung, Wing Ming
2002.
Monoamine oxidase inhibitors.
Expert Opinion on Therapeutic Patents,
Vol. 12,
Issue. 12,
p.
1813.
Naarding, P.
Kremer, H.P.H.
and
Zitman, F.G.
2002.
Enfermedad de Huntington: una revisión de las publicaciones sobre la prevalencia y el tratamiento de los fenomenós neuropsiquiátricos.
European psychiatry (Ed. Española),
Vol. 9,
Issue. 3,
p.
147.
Kapfhammer, H.-P.
2003.
Psychiatrie und Psychotherapie.
p.
1559.
Bonelli, Raphael M
and
Hofmann, Peter
2004.
A review of the treatment options for Huntington’s disease.
Expert Opinion on Pharmacotherapy,
Vol. 5,
Issue. 4,
p.
767.
Moro‐de‐Casillas, Maria L.
and
Riley, David E.
2005.
Drug Induced Movement Disorders.
p.
373.
Phillips, Wendy
Shannon, Kathleen M.
and
Barker, Roger A.
2008.
The current clinical management of Huntington's disease.
Movement Disorders,
Vol. 23,
Issue. 11,
p.
1491.
Kapfhammer, H. -P.
2008.
Psychiatrie und Psychotherapie.
p.
1501.
eLetters
No eLetters have been published for this article.